Heinrich B, Klein J, Delic M, Goepfert K, Engel V, Geberzahn L, Lusky M, Erbs P, Preville X, Moehler M
First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany.
Transgene SA, Illkirch-Graffenstaden.
Onco Targets Ther. 2017 May 2;10:2389-2401. doi: 10.2147/OTT.S126320. eCollection 2017.
Oncolytic virotherapy is an emerging immunotherapeutic modality for cancer treatment. Oncolytic viruses with genetic modifications can further enhance the oncolytic effects on tumor cells and stimulate antitumor immunity. The oncolytic vaccinia viruses JX-594-GFP+/hGM-CSF (JX-GFP) and TG6002 are genetically modified by secreting granulocyte-macrophage colony-stimulating factor (GM-CSF) or transforming 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU). We compared their properties to kill tumor cells and induce an immunogenic type of cell death in a human melanoma cell model using SK29-MEL melanoma cells. Their influence on human immune cells, specifically regarding the activation of dendritic cells (DCs) and the interaction with the autologous cytotoxic T lymphocyte (CTL) clone, was investigated. Melanoma cells were infected with either JX-GFP or TG6002 alone or in combination with 5-FC and 5-FU. The influence of viral infection on cell viability followed a time- and multiplicity of infection dependent manner. Combination of virus treatment with 5-FU resulted in stronger reduction of cell viability. TG6002 in combination with 5-FC did not significantly strengthen the reduction of cell viability in this setting. Expression of calreticulin and high mobility group 1 protein (HMGB1), markers of immunogenic cell death (ICD), could be detected after viral infection. Accordingly, DC maturation was noted after viral oncolysis. DCs presented stronger expression of activation and maturation markers. The autologous CTL clone IVSB expressed the activation marker CD69, but viral treatment failed to enhance cytotoxicity marker. In summary, vaccinia viruses JX-GFP and TG6002 lyse melanoma cells and induce additional immunostimulatory effects to promote antitumor immune response. Further investigation in vivo is needed to consolidate the data.
溶瘤病毒疗法是一种新兴的癌症免疫治疗方法。经过基因改造的溶瘤病毒可进一步增强对肿瘤细胞的溶瘤作用并刺激抗肿瘤免疫。溶瘤痘苗病毒JX - 594 - GFP+/hGM - CSF(JX - GFP)和TG6002通过分泌粒细胞 - 巨噬细胞集落刺激因子(GM - CSF)或将5 - 氟胞嘧啶(5 - FC)转化为5 - 氟尿嘧啶(5 - FU)进行基因改造。我们在使用SK29 - MEL黑色素瘤细胞的人黑色素瘤细胞模型中比较了它们杀死肿瘤细胞和诱导免疫原性细胞死亡的特性。研究了它们对人免疫细胞的影响,特别是关于树突状细胞(DC)的激活以及与自体细胞毒性T淋巴细胞(CTL)克隆的相互作用。黑色素瘤细胞单独感染JX - GFP或TG6002,或与5 - FC和5 - FU联合感染。病毒感染对细胞活力的影响呈时间和感染复数依赖性。病毒治疗与5 - FU联合使用导致细胞活力更强的降低。在这种情况下,TG6002与5 - FC联合使用并未显著增强细胞活力的降低。病毒感染后可检测到钙网蛋白和高迁移率族蛋白1(HMGB1)的表达,它们是免疫原性细胞死亡(ICD)的标志物。因此,病毒溶瘤后观察到DC成熟。DC呈现出更强的激活和成熟标志物表达。自体CTL克隆IVSB表达激活标志物CD69,但病毒治疗未能增强细胞毒性标志物。总之,痘苗病毒JX - GFP和TG6002可裂解黑色素瘤细胞并诱导额外的免疫刺激作用以促进抗肿瘤免疫反应。需要在体内进行进一步研究以巩固这些数据。